These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

830 related items for PubMed ID: 24777247

  • 1. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
    Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.
    Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
    [Abstract] [Full Text] [Related]

  • 2. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [Abstract] [Full Text] [Related]

  • 3. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M, Zeltsman M, McGee E, Adusumilli PS.
    Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
    [No Abstract] [Full Text] [Related]

  • 4. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 5. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.
    Cancer Res; 2010 Nov 15; 70(22):9053-61. PubMed ID: 20926399
    [Abstract] [Full Text] [Related]

  • 6. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.
    Mol Ther; 2019 Nov 06; 27(11):1919-1929. PubMed ID: 31420241
    [Abstract] [Full Text] [Related]

  • 7. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
    O'Hara M, Stashwick C, Haas AR, Tanyi JL.
    Immunotherapy; 2016 Nov 06; 8(4):449-60. PubMed ID: 26973126
    [Abstract] [Full Text] [Related]

  • 8. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ.
    Mol Ther; 2012 Mar 06; 20(3):633-43. PubMed ID: 22127019
    [Abstract] [Full Text] [Related]

  • 9. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 10. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.
    Hum Gene Ther; 2018 May 15; 29(5):614-625. PubMed ID: 29334771
    [Abstract] [Full Text] [Related]

  • 11. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ.
    Cancer Immunol Res; 2013 Jul 15; 1(1):43-53. PubMed ID: 24409448
    [Abstract] [Full Text] [Related]

  • 12. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 13. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH, Stashwick C, Plesa G, Tanyi JL.
    Immunotherapy; 2017 Aug 01; 9(9):767-780. PubMed ID: 28771103
    [Abstract] [Full Text] [Related]

  • 14. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.
    JCI Insight; 2018 Apr 05; 3(7):. PubMed ID: 29618658
    [Abstract] [Full Text] [Related]

  • 15. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
    Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, Li B, Lin S, Wang S, Wu Q, Liang Q, Li Y, Zhang X, Wu Y, Liu P, Yao Y, Pei D, Du X, Li P.
    J Hematol Oncol; 2017 Mar 13; 10(1):68. PubMed ID: 28288656
    [Abstract] [Full Text] [Related]

  • 16. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, Weder W, Renner C, Münz C, Petrausch U.
    Clin Cancer Res; 2018 Aug 15; 24(16):3981-3993. PubMed ID: 29748183
    [Abstract] [Full Text] [Related]

  • 17. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y, Wang K, Yue L, Zuo D, Sheng J, Lan S, Zhao Z, Dong S, Hu S, Chen X, Feng M.
    Pharmacol Res; 2024 May 15; 203():107186. PubMed ID: 38641176
    [Abstract] [Full Text] [Related]

  • 18. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P.
    Mol Ther; 2017 Nov 01; 25(11):2466-2476. PubMed ID: 28784559
    [Abstract] [Full Text] [Related]

  • 19. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.
    J Immunother; 2017 Apr 01; 40(3):104-107. PubMed ID: 28234665
    [Abstract] [Full Text] [Related]

  • 20. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
    Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ.
    Cancer Res; 2011 Jul 01; 71(13):4617-27. PubMed ID: 21546571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.